Last reviewed · How we verify
Valsartan+/- Hydrochlorothiazide
Valsartan+/- Hydrochlorothiazide is a Angiotensin II receptor blocker (ARB); combination with thiazide diuretic when applicable Small molecule drug developed by Novartis. It is currently FDA-approved for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction with left ventricular dysfunction.
Valsartan blocks angiotensin II receptors to relax blood vessels and lower blood pressure, while hydrochlorothiazide (when present) acts as a thiazide diuretic to reduce fluid volume.
Valsartan blocks angiotensin II receptors to relax blood vessels and lower blood pressure, while hydrochlorothiazide (when present) acts as a thiazide diuretic to reduce fluid volume. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction with left ventricular dysfunction.
At a glance
| Generic name | Valsartan+/- Hydrochlorothiazide |
|---|---|
| Sponsor | Novartis |
| Drug class | Angiotensin II receptor blocker (ARB); combination with thiazide diuretic when applicable |
| Target | AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (thiazide component) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, preventing angiotensin II-mediated vasoconstriction and aldosterone release, thereby reducing blood pressure and cardiac workload. Hydrochlorothiazide, when combined, enhances antihypertensive efficacy by inhibiting sodium reabsorption in the distal convoluted tubule, promoting urinary sodium and water excretion. The combination provides complementary mechanisms for blood pressure control.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Post-myocardial infarction with left ventricular dysfunction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Hypotension
- Hypokalemia (with HCTZ component)
- Hyperuricemia (with HCTZ component)
Key clinical trials
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Integration of Hypertension Management in HIV Care in Uganda (NA)
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- Role of ARNi in Ventricular Remodeling in Hypertensive LVH (PHASE2)
- BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333) (PHASE3)
- Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension (PHASE3)
- VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil (PHASE3)
- Hypertension and Cardiovascular Risk Factors (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valsartan+/- Hydrochlorothiazide CI brief — competitive landscape report
- Valsartan+/- Hydrochlorothiazide updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about Valsartan+/- Hydrochlorothiazide
What is Valsartan+/- Hydrochlorothiazide?
How does Valsartan+/- Hydrochlorothiazide work?
What is Valsartan+/- Hydrochlorothiazide used for?
Who makes Valsartan+/- Hydrochlorothiazide?
What drug class is Valsartan+/- Hydrochlorothiazide in?
What development phase is Valsartan+/- Hydrochlorothiazide in?
What are the side effects of Valsartan+/- Hydrochlorothiazide?
What does Valsartan+/- Hydrochlorothiazide target?
Related
- Drug class: All Angiotensin II receptor blocker (ARB); combination with thiazide diuretic when applicable drugs
- Target: All drugs targeting AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (thiazide component)
- Manufacturer: Novartis — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure with reduced ejection fraction
- Indication: Drugs for Post-myocardial infarction with left ventricular dysfunction
- Compare: Valsartan+/- Hydrochlorothiazide vs similar drugs
- Pricing: Valsartan+/- Hydrochlorothiazide cost, discount & access